Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Point-Of-Care HbA1c Analyzer Enhanced

By LabMedica International staff writers
Posted on 29 Mar 2011
A point-of-care (POC) immunoassay analyzer for diabetes management provides enhanced operator management and connectivity capabilities to meet the growing demands in POC testing for improved compliance management and data capture into patient records.

The DCA Vantage Analyzer ensures that all analyzers are running the same quality control regimen required by their institution and that only authorized operators are running the devices according to their specified access level.

The operator management capability has been expanded to support up to 1,000 operators, each with their unique access level as defined by their supervisor. More...
Another enhancement to the analyzer is the ability to display, print, and transmit the HbA1c reference ranges with the patient results, aiding in improved results interpretation.

POC managers are demanding better connectivity between their POC analyzers and the associated healthcare organization so that test results can be automatically transmitted to the laboratory and hospital information systems, and eventually to the patient's electronic medical record.

Siemens Healthcare Diagnostics (Erlangen, Germany) launched the DCA Vantage Analyzer with Version 3.0 software. It has the capacity to manage a larger number of operators while providing the required security access modes to prevent unauthorized use. In addition, the analyzer is one of the first hemoglobin A1c (HbA1c) POC analyzers in the industry to include the POCT1-A2 communication protocol. Use of this standard interface simplifies the connection to POC data management systems, enabling results to be automatically transmitted to the patient electronic medical record.

"We are focused on providing our customers with a trusted, clinically proven, point-of-care analyzer to better manage diabetes patients at the time of visit," said Dr. David Stein, CEO, POC business unit, Siemens Healthcare Diagnostics. "At the same time, we are continually looking at ways to enhance our products to meet the changing needs of our customers. These newly added features are important to point-of-care managers who are responsible for tests conducted at remote sites with multiple operators and devices in order to drive testing compliance."

Related Links:

Siemens Healthcare Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Electrolyte Analyzer
BKE-B
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.